An experimental Alzheimer's drug lowered tau protein and showed early signs of slowing decline in a study of about 400 people. Larger trials still need to confirm the benefit, but it points to a new treatment path beyond amyloid. Read more: https://apnews.com/article/d58728ee8f7d9dfd9ec8de416cddd75d @goodnews@fedigroups.social #GoodNews #Alzheimers #MedicalResearch #Dementia #HealthScience #ClinicalTrials